Corcept Therapeutics (CORT) Tops Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.85 +0.18%
EPS Growth %: -96.6%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -96.6%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $57.7 million versus the consensus estimate of $58.18 million.
GUIDANCE:
Corcept Therapeutics sees Q2 2018 revenue of $275-300 million, versus the consensus of $290.2 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
